minimizing impact on healthy tissues. Its platform is centered on generating high-affinity antibodies against these glycan structures, which have historically been difficult to target, allowing the development of modalities such as antibody-drug conjugates, T cell engagers, and multispecific antibodies. These therapies are designed to address solid tumors, including cancers that lack effective treatment options or show resistance to existing therapies.